Overview
- First book to address the potential of an immune response to the biopharmaceutical product
- Includes supplementary material: sn.pub/extras
Part of the book series: Biotechnology: Pharmaceutical Aspects (PHARMASP, volume VIII)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (13 chapters)
-
Front Matter
-
Back Matter
Keywords
About this book
A particular issue for biopharmaceuticals that has not been addressed comprehensively in any book, is the potential of an immune response to the biopharmaceutical product. That is, the human body marks the drug as a foreign body, and develops antibodies against the drug. These antibodies may be relatively harmless, but may also cross-react with the endogenous compound, causing autoimmunogenicity. Recent adverse experiences in Europe with Janssen-Ortho’s blockbuster product Eprex has increased the attention towards potential immunogenicity of biopharmaceuticals, above all from the regulatory agencies.
This book is intended to give a broad overview of the current state-of-the-art regarding the immune response to biopharmaceuticals. The chapters range from an overview of the immune system and factors that may trigger the immune system, via detection of antibodies and clinical implications, to various case examples and the regulatory view on immunogenicity.
Editors and Affiliations
Bibliographic Information
Book Title: Immunogenicity of Biopharmaceuticals
Editors: Marco van de Weert, Eva Horn Møller
Series Title: Biotechnology: Pharmaceutical Aspects
DOI: https://doi.org/10.1007/978-0-387-75841-1
Publisher: Springer New York, NY
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer-Verlag New York 2008
Hardcover ISBN: 978-0-387-75840-4Published: 21 March 2008
Softcover ISBN: 978-1-4419-2608-1Published: 19 November 2010
eBook ISBN: 978-0-387-75841-1Published: 06 February 2008
Edition Number: 1
Number of Pages: XII, 266
Topics: Pharmacology/Toxicology, Immunology
